Experienced in Aleukemic Leukemia Cutis (ALC)

Dr. Naveen M. Pemmaraju

Oncology | Hematology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Offers Telehealth
Experienced in Aleukemic Leukemia Cutis (ALC)
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Naveen Pemmaraju is an Oncologist and a Hematologist in Houston, Texas. Dr. Pemmaraju is rated as an Experienced provider by MediFind in the treatment of Aleukemic Leukemia Cutis (ALC). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 456 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 1
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Enrollment Status: Terminated
Publish Date: July 22, 2024
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Enrollment Status: Completed
Publish Date: June 06, 2023
Intervention Type: Other, Drug
Study Drug: LCL161 Smac Mimetic
Study Phase: Phase 2
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
A Phase Ib Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-EssentialThrombocythemia MF (Post-ET MF)
Enrollment Status: Terminated
Publish Date: November 15, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination With Azacytidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)
A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination With Azacytidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: Azacitidine, PLX51107
Study Phase: Phase 1
Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Enrollment Status: Withdrawn
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drugs: APG-1252, Ruxolitinib
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

456 Total Publications

Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation.
Author Correction: Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation.
Journal: Nature genetics
Published: August 11, 2025
Similar Doctors
Advanced in Aleukemic Leukemia Cutis (ALC)
Dr. Elham Abbasi-Hafshejani
Hematology Oncology | Oncology | Hematology
Advanced in Aleukemic Leukemia Cutis (ALC)
Dr. Elham Abbasi-Hafshejani
Hematology Oncology | Oncology | Hematology

North Houston Cancer Clinics PA

3115 College Park Dr, Suite 108, 
The Woodlands, TX 
 (34.7 miles away)
936-439-5213
Languages Spoken:
English, Farsi, Spanish
See accepted insurances
Accepting New Patients

Elham Abbasi-Hafshejani is a Hematologist Oncology specialist and an Oncologist in The Woodlands, Texas. Dr. Abbasi-Hafshejani is rated as an Advanced provider by MediFind in the treatment of Aleukemic Leukemia Cutis (ALC). Her top areas of expertise are Familial Colorectal Cancer, Breast Cancer, Paget Disease of the Breast, and Colorectal Cancer. Dr. Abbasi-Hafshejani is currently accepting new patients.

Advanced in Aleukemic Leukemia Cutis (ALC)
Dr. Munaf A. Alkadimi
Hematology Oncology | Oncology
Advanced in Aleukemic Leukemia Cutis (ALC)
Dr. Munaf A. Alkadimi
Hematology Oncology | Oncology

Oncology Consultants, P.A.

2130 W Holcombe Blvd, Fl 10, 
Houston, TX 
 (0.1 miles away)
713-600-0900
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Munaf Alkadimi is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Alkadimi has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Aleukemic Leukemia Cutis (ALC). His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Aleukemic Leukemia Cutis (ALC). Dr. Alkadimi is currently accepting new patients.

Experienced in Aleukemic Leukemia Cutis (ALC)
Dr. Carrie H. Yuen
Hematology Oncology | Hematology | Oncology
Experienced in Aleukemic Leukemia Cutis (ALC)
Dr. Carrie H. Yuen
Hematology Oncology | Hematology | Oncology

Tmh Physician Associates PLLC

6445 Main St, Fl 24, 
Houston, TX 
 (0.6 miles away)
713-441-3800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carrie Yuen is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Yuen is rated as an Advanced provider by MediFind in the treatment of Aleukemic Leukemia Cutis (ALC). Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Yuen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pemmaraju's expertise for a condition
ConditionClose
View All 11 Elite Conditions
View All 11 Distinguished Conditions
View All 13 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile